Literature DB >> 18677488

Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer.

Joerg Stattaus1, Steffen Hahn, Thomas Gauler, Wilfried Eberhardt, Stefan P Mueller, Michael Forsting, Susanne C Ladd.   

Abstract

The osteoblastic response (OR) phenomenon as a healing reaction during effective chemotherapy-defined by the appearance of new osteoblastic bone lesions while disease response in other tumor sites was well documented-has previously been described for breast and prostate cancer. The purpose of this study was to investigate this phenomenon that could erroneously be interpreted as progressive disease in patients with small cell lung cancer (SCLC) and to establish guidelines for interpretation of follow-up computed tomography (CT) examinations in this situation. Twenty-four patients with newly diagnosed SCLC and bone metastases were retrospectively included in this study. The characteristics of bone lesions in CT examinations were correlated with bone scintigraphy and magnetic resonance imaging, if available. In target lesions the CT density quantified in Hounsfield units (HU) was evaluated at baseline and during follow-up. New osteoblastic lesions occurred during follow-up in 17 of 24 patients. OR was proven in 4 patients and considered most likely in 11 patients; mean density increase in target lesions was 153 HU. The study indicates that osteoblastic response as a healing reaction seems to occur in the majority of patients with SCLC and bone metastases and should not be misinterpreted as progressive disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677488     DOI: 10.1007/s00330-008-1115-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  32 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC).

Authors:  E Felip; N Pavlidis; R A Stahel
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

3.  Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer.

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

Review 4.  Radiologic diagnosis of bone metastases.

Authors:  D I Rosenthal
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

5.  Bone scan flare predicts successful systemic therapy for bone metastases.

Authors:  R E Coleman; G Mashiter; K B Whitaker; D W Moss; R D Rubens; I Fogelman
Journal:  J Nucl Med       Date:  1988-08       Impact factor: 10.057

Review 6.  Bone imaging in metastatic breast cancer.

Authors:  Tsuyoshi Hamaoka; John E Madewell; Donald A Podoloff; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.

Authors:  I Brink; T Schumacher; M Mix; S Ruhland; E Stoelben; W Digel; M Henke; N Ghanem; E Moser; E U Nitzsche
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-17       Impact factor: 9.236

8.  Healing flare in skeletal metastases from breast cancer.

Authors:  M J Janicek; D F Hayes; W D Kaplan
Journal:  Radiology       Date:  1994-07       Impact factor: 11.105

9.  The bone scan flare phenomenon in non-small-cell lung cancer.

Authors:  Julie Lemieux; Jean Guimond; Francis Laberge; Carole St-Pierre; Yvon Cormier
Journal:  Clin Nucl Med       Date:  2002-07       Impact factor: 7.794

10.  Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria.

Authors:  Vito Amoroso; Frida Pittiani; Salvatore Grisanti; Francesca Valcamonico; Edda Simoncini; Vittorio D Ferrari; Giovanni Marini
Journal:  BMC Cancer       Date:  2007-06-01       Impact factor: 4.430

View more
  9 in total

1.  Osteoblastic healing response: discordant PET/CT findings.

Authors:  Filip Gemmel; Silvia A Eshuis; Femke van Vollenhoven; Paul Gemmel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-10-14       Impact factor: 9.236

Review 2.  Imaging pattern of calvarial lesions in adults.

Authors:  Jarred Garfinkle; Denis Melançon; Maria Cortes; Donatella Tampieri
Journal:  Skeletal Radiol       Date:  2010-06-06       Impact factor: 2.199

3.  Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.

Authors:  Connie Y Chang; F Joseph Simeone; Martin Torriani; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2017-06-30       Impact factor: 2.199

Review 4.  [Oncological imaging for therapy response assessment].

Authors:  J Stattaus
Journal:  Radiologe       Date:  2014-01       Impact factor: 0.635

5.  Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy.

Authors:  S Gourtsoyianni; S Hwang; D M Panicek; J Zheng; C Moskowitz; H Scher; M Morris; H Hricak
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

6.  MRI-Guided Cryoablation of Epidural Malignancies in the Spinal Canal Resulting in Neural Decompression and Regrowth of Bone.

Authors:  Thomas C Lee; Jeffrey P Guenette; Ziev B Moses; John H Chi
Journal:  AJR Am J Roentgenol       Date:  2018-09-24       Impact factor: 3.959

7.  Bone islands incidentally detected on computed tomography: frequency of enostosis and differentiation from untreated osteoblastic metastases based on CT attenuation value.

Authors:  Francesco Sala; Annarita Dapoto; C Morzenti; Maria Cristina Firetto; Clarissa Valle; A Tomasoni; Sandro Sironi
Journal:  Br J Radiol       Date:  2019-09-09       Impact factor: 3.039

8.  Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.

Authors:  Laure Fournier; Lioe-Fee de Geus-Oei; Daniele Regge; Daniela-Elena Oprea-Lager; Melvin D'Anastasi; Luc Bidaut; Tobias Bäuerle; Egesta Lopci; Giovanni Cappello; Frederic Lecouvet; Marius Mayerhoefer; Wolfgang G Kunz; Joost J C Verhoeff; Damiano Caruso; Marion Smits; Ralf-Thorsten Hoffmann; Sofia Gourtsoyianni; Regina Beets-Tan; Emanuele Neri; Nandita M deSouza; Christophe M Deroose; Caroline Caramella
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

9.  Systemic treatment in breast cancer: a primer for radiologists.

Authors:  Aya Y Michaels; Abhishek R Keraliya; Sree Harsha Tirumani; Atul B Shinagare; Nikhil H Ramaiya
Journal:  Insights Imaging       Date:  2015-11-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.